Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Medicus Pharma Ltd and keeping the price target at $20.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Jason McCarthy has given his Buy rating due to a combination of factors surrounding Medicus Pharma Ltd’s promising developments in their clinical programs. The company is advancing its novel therapeutic, a dissolvable microneedle patch for basal cell carcinoma, which has shown a remarkable complete response rate of over 60% in ongoing Phase 2 trials. This is significantly higher than the typical 20-30% response rate, indicating a strong potential to offer patients an alternative to invasive surgeries.
Additionally, Medicus Pharma Ltd is awaiting feedback from the FDA regarding their Type C meeting, which could provide clarity on the clinical pathway and potentially expand their current study into a registration study. The company’s expansion into the UAE with a new Phase 2 study further diversifies their clinical pipeline. These strategic moves, along with the anticipated updates on their Teverelix program, position Medicus Pharma Ltd as a promising investment opportunity.